ME
ALDR

McIlrath & Eck’s Alder Biopharmaceuticals ALDR Stock Holding History

McIlrath & Eck’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-600
Closed -$8K – 687
2019
Q2 		$8K Hold
600
– – ﹤0.01% 390
2019
Q1 		$8K Hold
600
– – ﹤0.01% 390
2018
Q4 		$6K Hold
600
– – ﹤0.01% 358
2018
Q3 		$10K Hold
600
– – 0.01% 294
2018
Q2 		$9K Hold
600
– – 0.01% 296
2018
Q1 		$8K Hold
600
– – ﹤0.01% 300
2017
Q4 		$7K Buy
+600
New +$6.7K ﹤0.01% 330

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $494M AUM 23.45% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

McIlrath & Eck's ALDR Position: Q3 2019 in Review

McIlrath & Eck sold out of Alder Biopharmaceuticals (ALDR) in Q3 2019, closing a stake of 600 shares — an estimated $8K sold.

McIlrath & Eck first reported a position in ALDR in Q4 2017 and held it in 7 quarters. The position peaked at $10K in Q3 2018. 143 funds tracked by Wall St. Rank hold ALDR as of Q3 2019.

  • McIlrath & Eck reported no remaining Alder Biopharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • McIlrath & Eck sold 600 Alder Biopharmaceuticals shares in Q3 2019, an estimated $8K.
  • McIlrath & Eck first reported a position in Alder Biopharmaceuticals in Q4 2017 and held it in 7 quarters.
  • McIlrath & Eck's Alder Biopharmaceuticals position peaked at $10K in Q3 2018.
  • 143 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2019.

Based on McIlrath & Eck's 13F filing for Q3 2019, filed 5 Nov 2019.